These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

713 related articles for article (PubMed ID: 14556449)

  • 1. [Intensive treatment of multiple myeloma].
    Harousseau JL
    Bull Acad Natl Med; 2003; 187(2):405-13; discussion 413-5. PubMed ID: 14556449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of stem cell transplantation in multiple myeloma.
    Harousseau JL; Attal M
    Blood Rev; 2002 Dec; 16(4):245-53. PubMed ID: 12350367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
    Lee CK; Barlogie B; Zangari M; Fassas A; Anaissie E; Morris C; Van Rhee F; Cottler-Fox M; Thertulien R; Muwalla F; Mazher S; Badros A; Tricot G
    Bone Marrow Transplant; 2002 Dec; 30(12):873-8. PubMed ID: 12476279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma.
    Harousseau JL; Attal M; Divine M; Milpied N; Marit G; Leblond V; Stoppa AM; Bourhis JH; Caillot D; Boasson M
    Bone Marrow Transplant; 1995 Jun; 15(6):963-9. PubMed ID: 7581098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
    Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F
    Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Stem cell transplantation in multiple myeloma].
    Fukuda S; Sunami K; Sezaki T
    Gan To Kagaku Ryoho; 1999 Sep; 26(10):1407-14. PubMed ID: 10500527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of multiple myeloma.
    San Miguel JF; Bladé Creixenti J; García-Sanz R
    Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant.
    Cheema PK; Zadeh S; Kukreti V; Reece D; Chen C; Trudel S; Mikhael J
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):686-93. PubMed ID: 19450753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive therapy in multiple myeloma.
    Harousseau JL
    Pathol Biol (Paris); 1999 Feb; 47(2):203-9. PubMed ID: 10192890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of up-front treatment with a double stem cell transplantation in multiple myeloma.
    Eom KS; Min CK; Lee S; Kim YJ; Kim SY; Kim HJ; Lee JW; Min WS; Kim CC
    Jpn J Clin Oncol; 2006 Jul; 36(7):432-8. PubMed ID: 16782727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma.
    Harousseau JL; Attal M; Divine M; Marit G; Leblond V; Stoppa AM; Bourhis JH; Caillot D; Boasson M; Abgrall JF
    Stem Cells; 1995 Aug; 13 Suppl 2():132-9. PubMed ID: 8520502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic bone marrow transplantation for the treatment of multiple myeloma. An overview of published reports.
    Cavo M; Benni M; Cirio TM; Gozzetti A; Tura S
    Stem Cells; 1995 Aug; 13 Suppl 2():126-31. PubMed ID: 8520501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
    Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
    Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma.
    Kasamon YL; Jones RJ; Diehl LF; Nayer H; Borowitz MJ; Garrett-Mayer E; Ambinder RF; Abrams RA; Zhang Z; Flinn IW
    Biol Blood Marrow Transplant; 2005 Jan; 11(1):39-46. PubMed ID: 15625543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.
    Wechalekar A; Amato D; Chen C; Keith Stewart A; Reece D
    Ann Hematol; 2005 Feb; 84(2):115-7. PubMed ID: 15503021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma.
    Cavo M; Bandini G; Benni M; Gozzetti A; Ronconi S; Rosti G; Zamagni E; Lemoli RM; Bonini A; Belardinelli A; Motta MR; Rizzi S; Tura S
    Bone Marrow Transplant; 1998 Jul; 22(1):27-32. PubMed ID: 9678792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.